SPY760.08+0.04%QQQ690.02−0.05%BTC/USD74,362.12+0.90%DIA524.59+0.03%GLD365.15−0.01%TLT80.95+0.04%

Kyverna Therapeutics Inc

KYTXNASDAQ

Trade with Public

$5.12

0.040.79%

Last update: Nov 11, 4:26 PM

Overview News Charts Earnings Forecast Events Financials Sentiment Ownership Compare Options Stock Report

Kyverna Therapeutics (KYTX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Kyverna Therapeutics (KYTX) stock.

Analyst Consensus — 6 Analysts

5Buy

1Hold

# Analysts6

Latest Upgrades and Downgrades for Kyverna Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
—	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$20→$25
—	JP Morgan	Brian Cheng	PT Cut	Overweight	$30→$29
—	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$20
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$31→$33
—	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$20→$25
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$27→$31
—	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$10→$20
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$24→$27
—	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$5→$10
—	William Blair	Sami Corwin	Initiate	Outperform	—
—	HC Wainwright & Co.	Mitchell Kapoor	Upgrade	Neutral→Buy	$4→$5
—	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$6→$4
—	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$40→$20
—	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$7→$6
—	Wells Fargo	Derek Archila	PT Cut	Overweight	$44→$24
—	UBS	Trung Huynh	Initiate	Buy	$13
—	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$7
—	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Neutral	$8→$7
—	JP Morgan	Brian Cheng	PT Cut	Overweight	$39→$33

Kyverna Therapeutics Inc

Kyverna Therapeutics (KYTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Kyverna Therapeutics Stock

Kyverna Therapeutics (KYTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Kyverna Therapeutics Stock

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

People Also Watch

People Also Watch

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

Kyverna Therapeutics Inc

Kyverna Therapeutics (KYTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Kyverna Therapeutics Stock

Kyverna Therapeutics (KYTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Kyverna Therapeutics Stock

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PROHC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PROJP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PROHC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PROWells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PROMorgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

People Also Watch

People Also Watch

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PROHC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PROJP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PROHC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PROWells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PROMorgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25